

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




Folic Acid

Ethylenediamine
EEDQ




Folate-NH₂



(EC), Sulfo-NHS, EDC

2) Na^{99m}TcO₄ / SnCl₂



^{99m}Tc-EC-folate




FIG. 1





FIG 2





FIG. 3




FIG. 4





FIG. 5

© 1997 Blackwell Science Ltd, *Journal of Clinical Pharmacy and Therapeutics*, 22, 339–344

FIG. 6A
Tc-99m EC-folate
Tc-99m EC



FIG. 6B
Tc-99m EC-folate
Tc-99m EC



குடும்ப தெரு மூலம் காலத்திலே விடப்பட்டிருக்கிறது






FIG. 7



EC

2-Nitroimidazole - NH₂

- 1) EDC, Sulfo-NHS
 2) NaTcO₄ / SnCl₂




FIG. 8A




FIG. 8B




FIG. 9




FIG. 10

புது திரும்பு வெள்ளி நீர் காலை

FIG. 11A



FIG. 11B



காலை காலை காலை காலை காலை



FIG. 12

3-10-1999

EC-(2-HIM)2 after adding serum 3:-

Date: Mar 10 1999
Data File:

Start time: 16:02

Scum time: 00:00:50
Plate: 1 Lane: 1

Elect Resolution: NORMAL

(Amp. Range: 0 - 2047)

Stop counts: 50000

Stop Counts Region: 0.00 to 20.00 cm

Rf Calculations: Origin: 1.50 cm

Integration Parameters: Auto Integration

Peak slope: 1.0

Solvent Front: 19.00 cm

Min width: 0.1 Min %: 2.0

Total Count Region: 0.00cm to 20.00cm

Total Counts: 53170

Total CPM: 63810

Reg. #	Start (cm)	Stop (cm)	Center (cm)	Rf	Region Counts	Region CPM	% of Tot Reg	% of Tot Cnt
1	0.60	4.40	2.50	0.06	4557	5468	9.02	8.57
2	8.20	16.80	12.56	0.63	45980	55180	90.98	86.48
TOTAL					50540	60650	100.00	95.05

DRAFT COPY - DO NOT DISTRIBUTE





FIG. 13

FIG. 14A



பிரதிவேகம் தான் கீழ்க்கண்ட படங்களில்

No Treatment

Paclitaxel Treated




FIG. 14B

இந்த படங்கள் சூரிய விடுதியை விட்டு

^{99m}Tc -EC ^{99m}Tc -EC-NIM



^{99m}Tc -EC ^{99m}Tc -EC-NIM




FIG. 15A

கிரி காலை நீர் = குத்து குத்து குத்து குத்து

99m Tc-EC-Nitroimidazole (NIM)
(100 μ Ci/mouse, iv.)




FIG. 15B

□ □ □ □ □ □ □ □ □ □

99m Tc-EC-Nitroimidazole (NIM)




FIG. 15C

புது தென்னிந்திய கலை மற்றும் பண்டிகை

^{99m}Tc -EC-Nitroimidazole (NIM)
(100 $\mu\text{Ci}/\text{mouse, iv.}$)








FIG. 15D



(1) Sulfo-NHS, EDAC

L-GAP

EC



EC-GAP

Synthesis of EC-GAP

FIG.

புது தாழ்வு கொடுத்து நினைவு செய்யப்படுகிறது




FIG. 17






FIG. 18

புது எடுப்பு காலை விரைவு காலை


15 Min.



30 Min.



1 Hour



2 Hour




FIG. 19A

0 0 T e S G " E S T C S S S 0


99m Tc-EC-Annexin V
(100 μ Ci/mouse, iv.)



FIG. 19B

□ □ T C E G D □ □ □ □ □ □ □

99m Tc-EC-Annexin V
 99m Tc-EC
 99m Tc-EC-Annexin V



99m Tc-EC-Annexin V
 99m Tc-EC
 99m Tc-EC-Annexin V



FIG. 20A

Digitized by srujanika@gmail.com

^{99m}Tc -EC-Annexin V
($100\mu\text{Ci}/\text{mouse, iv.}$)




FIG. 20B






FIG. 21




FIG. 22




FIG. 23

$\log \frac{R}{R_0} = 0.62 \pm 0.00$




FIG. 24 OSE 4.100

^{99m}Tc-ECD Colchicine (1 Hour Post Injection)



0950941522 - 09524000

FIG. 25

99m Tc-EC (Control) (1 Hour Postinjection)

© 1999 JOURNAL OF CLINICAL ONCOLOGY

FIG. 26




FIG. 27. FIGURE 27

000000000000000000000000

FIG. 28




FIG. 29






FIG. 30




FIG. 31

FIG. 32



0 9 5 9 9 4 6 2 0 6 2 4 0 0

FIG. 33



100 T 20 50 " 500 F 100 G 200 H

FIG. 34







FIG. 35





(1) Sulfo-NHS, EDAC
(2) NaTcO₄/SnCl₂




^{99m}Tc-EC-Neomycin

Synthetic scheme of ^{99m}Tc-EC-neomycin.

FIG. 36

^{99m}Tc -EC ^{99m}Tc -EC-Neomycin



Planar image of breast tumor-bearing rats after administration of ^{99m}Tc -EC and ^{99m}Tc -EC-Neomycin (100 $\mu\text{Ci}/\text{rat}$, iv.) showed that the tumor could be well visualized from 0.5-4 hours postinjection.

FIG. 37A

Scintigraphic image of breast tumor-bearing rats after

administration of ^{99m}Tc -EC and ^{99m}Tc -EC-neomycin (100

$\mu\text{Ci}/\text{rat}$, iv.) showed that the tumor could be well visualized from 0.5-4 hours postinjection.

WOO IN JA
SCINTIMAMMOGRAPHY EC-NEO

753717 E63
2000

WONKWANG UNIV HOSP




FIG. 37B Scintimammography with 99m Tc-EC- neomycin (30 mCi, iv.) of a breast cancer patient. Images taken two hours post-injection.

EC




FIG. 38A ^1H NMR of PFC-100

Neomycin




FIG. 38B

¹H-NMR of neomycin.





FIG. 38C

¹H-NMR of EC-neomycin.

EC - Neo 1 (Orn) / 5 (Orn) 1) III



/export/home/marriott/data/ecneo_10.dhb/4ret/pdata/1 unknown Thu Mar 23 14:05:59 2000

FIG. 39

Mass spectrometry of EC-neomycin (M^+ 1112.55).

UV Wavelength Scan of EC




FIG. 40A

UV wavelength scan of EC.

UV Wavelength Scan of Neomycin




FIG. 40B

UV wavelength scan of neomycin.

UV Wavelength Scan of EC-Neomycin




FIG. 40C

UV wavelength scan of EC-neomycin.

SUMMARY REPORT

EC-NEOMYCIN 30mg + EC

**Tc-99m
METHANOL-AMMONIUM ACETATE**

Date: Feb 03 2000 Start time: 12:45 Accum time: 00:03:01
Data File: Plate: 1 Lane: 1

Elect Resolution: NORMAL (Amp. Range: 0 - 2047)
Rf Calculations: Origin: 0.00 cm Solvent Front: 20.00 cm
Integration Parameters: Auto Integration
Peak slope: 1.0 Min width: 0.1 Min %: 2.0

Total Count Region: 0.00cm to 20.00cm

Total Counts: 48360

Total CPM: 16030

Reg. #	Start (cm)	Stop (cm)	Center (cm)	Rf	Region Counts	Region CPM	% of Tot Reg	% of Tot Cnt
1	6.50	14.90	10.57	0.53	45000	14920	100.00	93.05
TOTAL					45000	14920	100.00	93.05




FIG. 41

Radio-TLC analysis of 99m Tc-EC-neomycin.

99m Tc-EC-NEO

Column: Bio-Rad Carbohydrate, Aminex HPX-87C, 250x4mm

Eluent: H₂O

Flow Rate: 0.4ml/min

Detector: Radiochemical

Temp: 85.0°C




FIG. 42 HPLC analysis of 99m Tc-EC-neomycin (radioactive detector).

^{99m}Tc-EC-NEO


Column: BioRad Carbohydrate, Aminex IPX-87C, 250x4mm

Eluent: H₂O

Flow Rate: 0.4ml/min

Detector: UV, 254nm

Temp: 85.0°C



RUN# 2 JAN 28, 1999 00:54:29

RT	WREH	TYPE	WIDTH	WREH%
3.315	153606480	SPH	.498	99.71165
5.145	392604	BV	.265	.15126
5.680	255901	VB	.132	.13712

TOTAL WREH=2.5955E+08
NUC. FACTOR=1.0000E+00

FIG. 43

HPLC analysis of ^{99m}Tc-EC-neomycin (UV 254 nm).

¹⁸F-FDG

Column: Bio-Rad Carbohydrate,
Aminex HPX-87C, 250x4mm
Eluent: H₂O
Flow Rate: 0.4ml/min
Detector: Radiochemical
Temp: 85.0°C


* TIME 15:19:00
JAN 28, 1999 15:19:00

* UHT SP = 0
* RTT C = 0
* THRESH = 0
* LINSI = 100
MAX CAPACITY = 1244

ZERU = 0. -1.428
RTT C = 0
UHT SP = 0.0
RTK REC = 0
THRESH = 0
RT NU = 0.94

* RUN # 1 JAN 28, 1999 15:31:29

SIMPLI



KUN# 1 JAN 28, 1999 15:31:29

SIMPLI

RT	NAME	TYPE	WIDIN	AREH%
4.284	108-12040	AREL	AV	0.0000.001

TOTAL AREH=1.03/1E+08
MOL FRACTION=1.0000E+00

FIG. 44

HPLC analysis of ¹⁸F-FDG (radioactive detector).

¹⁸F-FDG


DATE 1/28/99
JAN 28, 1999 00:16:15

• CHT SP .5 0
• ATT 2 3 0
• THRESH 7 0
• LIST: LIST
PERK CAPACITY: 1244

ZERO = 0. -11.179
ATT 3 = 3
CHT SP = 0.5
WR REJ = 0
THRESH = 7
Pr. WD = 0.04

• RUN # 1 JAN 28, 1999 00:37:02

START



RUN# 1 JAN 28, 1999 00:37:02

Column: Bio-Rad Carbohydrate,
Aminex HPX-87C, 250x4mm

Eluent: H₂O

Flow Rate: 0.4ml/min

Detector: UV, 254nm

Temp: 85.0°C

FIG. 45

© 1995-2001 JGEG - All Rights Reserved

HPLC analysis of ¹⁸F-FDG (UV 254 nm).

% of Drug Uptake in Lung Cancer Cell Line (A549)




FIG. 46

In vitro cellular uptake assay of a series of ^{99m}Tc -EC drug conjugates in lung cancer cell line. ^{99m}Tc -EC-neomycin showed highest uptake in the agents tested.

% of Drug Uptake in Human Lung Cancer Cell Line (A549)




FIG. 47
Effect of glucose on cellular (A549) uptake of ^{99m}Tc -EC-neomycin and ^{18}F -FDG.

% of Drug Uptake in Human Lung Cancer Cell Line (H1299)





FIG. 48A

Effect of glucose on cellular (H1299) uptake of ^{99m}Tc -EC-neomycin and ^{18}F -FDG.


Effects of Glucose Loading on 99m Tc-EC-Neomycin in Human Lung Cancer Cell Line (H1299)



Doses of EC-NEO = 0.625, 1.00
FIG. 48B

Synthesis of ^{99m}Tc -EC-Glucosamine


FIG. 49



Hexokinase Assay of Glucose

WAVELENGTH SCAN/0

03/01/00 14:41




301.5 nm 0.889 ABS
342.0 nm 2.044 ABS

FIG. 50

Hexokinase Assay of Glucosamine

WAVELENGTH SCAN/0

03/01/00 14:50




301.5 nm 0.193 ABS
341.5 nm 0.360 ABS

FIG. 51

Hexokinase Assay of EC-Glucosamine

WAVELENGTH SCAN/0

03/01/00 14:45




302.5 nm 1.897 ABS
341.5 nm 0.523 ABS

FIG. 52

Hexokinase Assay of EC-GAP-Glucosamine

WAVELENGTH SCAN/0

03/01/00 15:37



302.0 nm 1.620 ABS

FIG. 53





FIG. 54 Synthesis of ^{99m}Tc -EC-GAP-Glucosamine

In Vitro Cellular Uptake of 99m Tc-EC in Human Lung Cancer Cell Line (A549)



Scintigraphy - FIG. 55A

In Vitro Cellular Uptake of 99m Tc-EC-DG-GAP in Human Lung Cancer Cell Line (A549)




FIG. 55B

In Vitro Cellular Uptake of ^{18}FDG in Human Lung Cancer Cell Line (A549)





FIG. 55C

**Tumor-to-tissue count density ratios of 99m Tc-EC-GAP in breast tumor-bearing rats
(n=3/interval; 10 μ Ci/rat, IV)**



In Vitro Cellular Uptake of ^{18}FDG with Glucose Loading at 2 Hours Post-Injection in Breast
Cancer Cell Line (13762)




FIG. 57

% Uptake of 99m Tc-EC-Neomycin in Breast Tumor-Bearing Rats




FIG. 58




FIG. 59

Synthetic scheme of ^{99m}Tc -EC-dideoxyglucose.




FIG. 60 Mass spectrometry of EC-deoxyglucose.




FIG. 61

 ^1H -NMR of EC-deoxyglucose (EC-DG).

Glucosamine




FIG. 62

^1H -NMR of glucosamine.

0653528480

04-03 18:55 MON FROM: WON KWANG H
Method: _DEFAULT File: BABGCCAF.R01


0653528480

data User: EC-Glucosami

TO: 6117137453372

PAGE: 01

(99m Tc - DG TLC)

DEFAULT: BABGCCAF.R01-H-3Method: BABGCCAF.R01

Channel:	Detector:						
		Start - End	RT	Height (cps)	Area (Counts)	%Total (%)	%ROI (%)
Bkg 1		0: 00-	2: 19	1: 09	539.7		
Rgn 1		2: 19-	3: 02	2: 47	31606.2	263570.8	97.99 100.00
Bkg 2		3: 02-	3: 27	3: 14	250.1		
I Peak					263570.8	97.99	100.00

Total Area = 268986.1 Counts
Bkg Area = 89999.9 Counts
Unallocated = 5415.3 Counts (2.01%)

Trace Parameters: BABGCCAF.R01 H-3

Trace Display Smoothing: 0.0 s
Trace Display Shift: 0.0 s
Trace Display Factor: 1.000
Channel Shift: 0.0 s
Channel Factor: 1.000

Regions were added manually.

FIG. 63


Radio-TLC analysis of ^{99m}Tc-EC-DG.

^{99m}Tc -EC-deoxyglucose

^{99m}Tc -EC

Radioactive Scan

EC $\text{Tc} - 99\text{m}$



RUN# 6 MAR 30, 1999 15109139

AREAX RT AREA TYPE WIDTH AREAX
3.781 16671194 BY .910 100.00000


TOTAL AREA=1.6671E+07

FIG. 64

HPLC analysis of ^{99m}Tc -EC-deoxyglucose and ^{99m}Tc -EC-
(radioactive detector). [GE 2000] [GC]

^{99m}Tc -EC-deoxyglucose + ^{99m}Tc -EC
(mixed)

Radioactive Scan



Mixed $\text{Tc}-^{99m}$
EC-Deoxy-Glucose
EC

RUN# 7 MAR 30, 1999 15132137

AREAX				
RT	AREA	TYPE	WIDTH	AREAX
3.355	22173760	BV	.448	58.46186
3.918	21767872	VV	.387	49.53814

TOTAL AREA=4.3942E+07
MUL FACTOR=1.0000E+00


FIG. 65

HPLC analysis of ^{99m}Tc -EC-deoxyglucose and ^{99m}Tc -EC
(radioactive detector, mixed).

Hexokinase Assay of Glucose

WAVELENGTH SCAN/0

03/01/00 14:41



301.5 nm 0.889 ABS
342.0 nm 2.044 ABS


FIG. 66

Hexokinase assay of glucose.

Hexokinase Assay of FDG

WAVELENGTH SCAN/0

03/09/00 14:34



340.0 nm 1.906 ABS
346.5 nm 1.351 ABS


FIG. 67

Hexokinase assay of FDG.

Hexokinase Assay of EC-Glucosamine (EC-DG)

WAVELENGTH SCAN/0

03/01/00 14:45



302.5 nm 1.897 ABS
341.5 nm 0.523 ABS

FIG. 68

Hexokinase assay of EC-DG.

% of Drug Uptake in Lung Cancer Cell Line (A549)




FIG. 69

In vitro cellular uptake assay of ^{99m}Tc -EC-deoxyglucose, ^{99m}Tc -EC and ^{18}F -FDG in lung cancer cell line (A549). ^{99m}Tc -EC-DG showed similar uptake compared to ^{18}F -FDG.

In Vitro Cellular Uptake of 99m Tc-EC-DG in Breast Cancer Cells after Glucose Loading (2 hours
incubation; 2uCi/well; 50,000 cells/well; 0.5mL/well)




FIG. 70 Effect of d- and L-glucose on breast cellular (13762 cell line) uptake of 99m Tc-EC-DG.

In Vitro Cellular Uptake of ^{18}F FDG in Breast Cancer Cells after Glucose Loading (2 hours
incubation; 2uCi/well; 50,000 cells/well; 5mL./well)




FIG. 71

Effect of d- and L-glucose on breast cellular (13762 cell line)
uptake of ^{18}F -FDG.

In Vitro Cellular Uptake of ^{18}FDG in Lung Cancer Cells after Glucose Loading (2 hours incubation;
 2uCi/well; 50,000 cells/well; 5mL/well)




FIG. 72

Effect of d- and L-glucose on lungcellular (A549 cell line) uptake of
 ^{18}F -FDG.

In Vitro Cellular Uptake of ^{99m}Tc -EC-DG in Lung Cancer Cells after Glucose Loading (2 hours
incubation; 2uCi/well; 50,000 cells/well; 0.5mL/well)




FIG. 73

Effect of d- and L-glucose on breast cellular (A549 cell line) uptake
of ^{99m}Tc -EC- DG.

Effect of Intravenous Injection of Glucosamine and EC-DG on Blood Glucose Level in Rats




FIG. 74
Effect of *in vivo* blood glucose level induced by glucosamine and
EC-DG (1.2 mmol/kg, i.v.).

Effect of Intravenous Injection of FDG and FDG+Insulin on Blood Glucose Level in Rats




FIG. 75

Effect of *in vivo* blood glucose level induced by FDG (4.5 and 1.9 mmol/kg, i.v.) and insulin.

Tumor-to-Tissue Count Density Ratios of ^{99m}Tc -EC-Deoxyglucose in Breast Tumor-Bearing Rats




FIG. 76

Tumor-to-tissue count density ratios of ^{99m}Tc -EC-deoxyglucose in breast tumor-bearing rats.

In Vivo Uptake of ^{99m}Tc -EC-Deoxyglucose in Breast Tumor-Bearing Rats




FIG. 77

In vivo biodistribution of ^{99m}Tc -EC-deoxyglucose in breast tumor-bearing rats.

In Vivo Uptake of ^{99m}Tc -EC-Deoxyglucose in Lung Tumor-Bearing Nude Mice




FIG. 78

In vivo tissue uptake of ^{99m}Tc -EC-deoxyglucose in lung tumor-bearing mice.

In Vivo Uptake of ^{99m}Tc -EC-Neomycin in Lung Tumor-Bearing Nude Mice




FIG. 79

In vivo tissue uptake of ^{99m}Tc -EC-neomycin in lung tumor-bearing mice.
■ 30 MIN ■ 2 HOURS ■ 4 HOURS

In Vivo Uptake of ^{18}FDG in Lung Tumor-Bearing Nude Mice





FIG. 80

In vivo tissue uptake of ^{18}F - FDG in lung tumor-bearing mice.

^{99m}Tc -EC

^{99m}Tc -EC-Glucose(6)



0.5 2 4hrs

0.5 2 4hrs

Planar image of breast tumor-bearing rats after administration of ^{99m}Tc -EC and ^{99m}Tc -EC-Glucose(6) ($100\mu\text{Ci}/\text{rat}$, iv.) showed that the tumor could be well visualized from 0.5-4 hours postinjection.

FIG. 81

Planar image of breast tumor-bearing rats after administration of ^{99m}Tc -EC and ^{99m}Tc -EC-Glucose(6) ($100\mu\text{Ci}/\text{rat}$, iv.) showed that the tumor could be well visualized from 0.5-4 hours

Case 1 / 42

Dx : oligodysplastic astrocytoma



FIG 82A

FIG. 82A

© 1990 JES 2 - GE 100

| 05 | 0 |


NA YOUNG SOON

697800 F42


03/08/00 WONKWANG HOSP




5




6




7



8




9




10


INFERIOR->SUPERIOR




11




12




13




14




15



16




17



18



19




20

EC-DG Scan

99mTc-EC-DG 250 mCi

Case 176
Large glioblastoma with hemorrhage



[Fig 83A] Post-OP

FIG. 83A MRI of patient with hemorrhagic astrocytoma.

SEO OK RI

785085 R1

WONKWANG UNIV HOSP



99mTc EC DG 1.5H

13



14



15




16

13



19

14



22

15



25

16



28

INFERIOR -> SUPERIOR

^{133}C -DG Scan POD-26D

□□□□□□□□□□□□□□□□□□□□

FIG. 83B

SPECT with $^{99\text{m}}\text{Tc}$ -EC-DG of a patient with astrocytoma.

(Case 5) : M/F 62

Dx : Meningioma




FIG. 84A

MRI of a patient with benign meningioma.




FIG. 84B

SPECT with ^{99m}Tc -EC-DG of a patient with benign meningioma

(a) (b) (c)

U/F: Pulmonary (only necrotic material on biopsy)

TB pleurisy




FIG. 85A

CT of a patient with TB in lung.

LERMAN SUN

74.8 MBq

0.4 mm

MONKWANG

INFRA

GSP


99m Tc EC DG 40MIN

5

6

7

8





9

10

11

12

INFERIOR->SUPERIOR




13

14

15

16



17

18

19

20

0.4 mm 0.4 1.00 = 0.625 1.00

FIG. 85B

SPECT with 99m Tc-EC-DG of a patient with TB showed no focal

Case 5 : 59/M


Dx: Squamous carcinoma



Pre RTX



Post RTX



Pre RTX



FIG. 86A

CT of a patient with lung cancer.


JUNG KI WOON

EC DG 1H

758434 M59

10Apr2000

WONKWANG UNIV HOSP



ANT
LUNG CANCER POST RTX 1MK

ANT

E.G. T

E.G. T

FIG. 86B





Whole body images of ^{99m}Tc -EC-DG of a patient with lung cancer.

JUNG-SIK MOON

7581344459

1.0A³B²C⁰D⁰E⁰F⁰G⁰H⁰I⁰J⁰K⁰L⁰M⁰N⁰O⁰P⁰Q⁰R⁰S⁰T⁰U⁰V⁰W⁰X⁰Y⁰Z⁰

WONKWANG UNIV HOSP



EC DG 1H 30 MIN LUNC CANCER POST RTX 1WK

FIG. 86C

SPECT with 99m Tc-EC-DG of a patient with lung cancer, the tumor showed focal intense uptake.